C12N 2760/18532
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2760/18532 (Use of virus as therapeutic agent, other than vaccine) appears on 13 US grants and 15 published applications in this corpus.
Search patents in C12N- Granted patents
- 13
- Published applications
- 15
- Assignees
- 10
- Inventors
- 25
- Latest grant
- 26 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 2 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 1 |
| 2014 | 0 | 0 |
| 2015 | 4 | 2 |
| 2016 | 2 | 1 |
| 2017 | 1 | 1 |
| 2018 | 2 | 1 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 1 |
| 2023 | 1 | 2 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
By publication year.
Recent patents
- Composition comprising NC886 for improving oncolytic virus activity or production26 Aug 2025US 12,398,376 B2National Cancer Center
- Method of targeting oncolytic viruses to tumors21 Mar 2023US 11,607,426 B2The United States Government as represented by the Department of Veterans Affairs
- Respiratory syncytial virus with a genomic deficiency complemented in trans6 Apr 2021US 10,967,014 B2De Staat der Nederlanden, vert. door de minister van VWS
- Tissue targeted antigenic activation of the immune response to treat cancers2 Oct 2018US 10,086,066 B2Qu Biologics Inc.
- Respiratory syncytial virus with a genomic deficiency complemented in trans13 Feb 2018US 9,889,168 B2De Staat der Nederlanden, vert. door de minister van VWS
- Method for treating tumor with combination of exogenous antigen and therapeutic agent17 Oct 2024US 2024/0342266 A1Guangzhou Anjie Biomedical Technology CO., LTD.
- Method of targeting oncolytic viruses to tumors16 Nov 2023US 2023/0364147 A1The United States Government as represented by the Department of Veterans Affairs
- Cellular compositions and methods of treatment21 Sep 2023US 2023/0293590 A1Mesoblast International Sarl
- Composition comprising nc886 for improving oncolytic virus activity or production27 Jan 2022US 2022/0025338 A1National Cancer Center
- Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers23 Apr 2020US 2020/0121784 A1Qu Biologics Inc.
Most cited
By later US patents
- Tissue targeted antigenic activation of the immune response to treat cancers13US 9,107,864 B2Qu Biologics Inc. · 2015
- Respiratory syncytial virus with a genomic deficiency complemented in trans7US 9,107,939 B2De Staat der Nederlanden, vert. door de minister van VWS · 2015
- Tissue targeted antigenic activation of the immune response to treat cancers5US 9,775,896 B2Qu Biologics Inc. · 2017
- Tissue targeted antigenic activation of the immune response to treat cancers2US 10,086,066 B2Qu Biologics Inc. · 2018
- Methods and compositions for treatment of cancer using oncolytic RSV activity2US 9,241,998 B2Board of Regents, The University of Texas System · 2016